27 years of historical data (1998–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arbutus Biopharma Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $895M | $607M | $415M | $352M | $413M | $269M | $159M | $212M | $276M | $130M | $202M |
| Enterprise Value | $859M | $572M | $397M | $333M | $323M | $240M | $130M | $175M | $234M | $119M | $36M |
| P/E Ratio → | -12.26 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 144.95 | 98.35 | 22.87 | 9.01 | 37.61 | 38.94 | 26.40 | 35.90 | 25.83 | 86.65 | 8.13 |
| P/B Ratio | 8.88 | 6.23 | 3.91 | 2.57 | 2.44 | 2.64 | 2.18 | 1.06 | 1.51 | 0.64 | 0.37 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 92.68 | 21.90 | 8.55 | 29.39 | 34.64 | 21.67 | 29.64 | 21.87 | 79.05 | 1.43 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Arbutus Biopharma Corporation earns an operating margin of -1236.7%. Operating margins have compressed from -167.8% to -1236.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -68.8% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -586.7% | -858.3% | -881.4% | -486.0% | -3986.7% | -107.1% |
| Operating Margin | -1236.7% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | -2394.0% | -1522.0% | -1036.4% | -32773.3% | -411.4% |
| Net Profit Margin | -1133.0% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | -2557.4% | -967.8% | -788.8% | -25606.7% | -245.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.8% | -68.8% | -60.0% | -45.4% | -56.2% | -73.0% | -112.6% | -29.8% | -43.8% | -102.3% | -19.2% |
| ROA | -50.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | -92.2% | -24.6% | -32.9% | -77.7% | -14.7% |
| ROIC | -75.9% | -75.9% | -56.6% | -49.7% | -72.9% | -74.4% | -104.0% | -44.4% | -50.1% | -128.8% | -38.7% |
| ROCE | -64.1% | -64.1% | -54.9% | -36.8% | -45.8% | -51.3% | -91.5% | -40.6% | -45.2% | -101.7% | -25.4% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $36M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.08 | 0.09 | 0.11 | 0.22 | 0.05 | — | 0.07 | 0.06 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.36 | -0.17 | -0.13 | -0.53 | -0.29 | -0.39 | -0.18 | -0.23 | -0.06 | -0.30 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -557.07 | -557.07 | -170.16 | -37.92 | -25.73 | -14.41 | -68.26 | -449.00 | -424.90 | — | — |
Net cash position: cash ($36M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
Arbutus Biopharma Corporation's current ratio of 8.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.60x to 8.15x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.15 | 8.15 | 5.87 | 4.60 | 14.32 | 13.38 | 11.99 | 11.50 | 10.87 | 12.51 | 17.38 |
| Quick Ratio | 8.15 | 8.15 | 5.87 | 4.60 | 14.32 | 13.38 | 11.99 | 11.50 | 10.87 | 12.51 | 17.28 |
| Cash Ratio | 7.85 | 7.85 | 5.60 | 4.47 | 13.84 | 12.92 | 11.60 | 11.09 | 10.62 | 12.31 | 17.14 |
| Asset Turnover | — | 0.05 | 0.13 | 0.20 | 0.05 | 0.05 | 0.06 | 0.03 | 0.05 | 0.01 | 0.03 |
| Inventory Turnover | 48.23 | — | — | — | — | — | — | — | — | — | 48.23 |
| Days Sales Outstanding | — | 142.49 | 35.73 | 12.65 | 29.86 | 69.26 | 73.11 | 88.53 | 29.68 | 168.87 | 20.28 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arbutus Biopharma Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 2.9% | — | — | 4.8% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 2.9% | 0.0% | 0.0% | 4.8% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $186M | $166M | $151M | $106M | $76M | $57M | $55M | $55M | $53M | $45M |
Compare ABUS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ABUSYou | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 27 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABUS stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonArbutus Biopharma Corporation's current P/E ratio is -12.3x. The historical average is 2.4x.
Arbutus Biopharma Corporation's return on equity (ROE) is -68.8%. The historical average is -51.7%.
Based on historical data, Arbutus Biopharma Corporation is trading at a P/E of -12.3x. Compare with industry peers and growth rates for a complete picture.
Arbutus Biopharma Corporation has 100.0% gross margin and -1236.7% operating margin.